<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615835</url>
  </required_header>
  <id_info>
    <org_study_id>067.3</org_study_id>
    <nct_id>NCT01615835</nct_id>
  </id_info>
  <brief_title>EnSite NavX-Guided Coronary Sinus Mapping During CRT Implant</brief_title>
  <acronym>Bi-VNavX</acronym>
  <official_title>Mapping in the Coronary Sinus During Implant of a Bi-Ventricular Implantable Cardioverter Defibrillator Utilizing the NavX Mapping System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of the EnSite NavX system to map the coronary vasculature during CRT implant&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective(s):&#xD;
&#xD;
      To determine the feasibility of CS mapping with NavX during Biventricular Implantable&#xD;
      Cardioverter Defibrillator (BiV ICD) implantation.&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
        -  Subject is between the age of 18 and 75 years&#xD;
&#xD;
        -  Subject is willing and able to sign a study specific informed consent&#xD;
&#xD;
        -  Subject is able to fulfill study requirements&#xD;
&#xD;
        -  Meet the conventional criteria for implant of a BiV ICD, including; LVEF of ≤35%, QRS ≥&#xD;
           120 ms and NYHA III-IV&#xD;
&#xD;
        -  Have persistent CHF symptoms despite contemporary CHF medical therapy&#xD;
&#xD;
        -  Stable and optimal medical therapy (stability is no changes in past 3 months).&#xD;
&#xD;
        -  Documented history of ischemic or non-ischemic cardiomyopathy.&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        -  Have any standard device exclusions including tricuspid valve prosthesis/ replacement.&#xD;
&#xD;
        -  Have a positive urine or serum pregnancy test (if female and of childbearing potential)&#xD;
&#xD;
        -  Be currently participating in an IDE or IND study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine feasibility of CS mapping with EnSite NavX during CRT implant</measure>
    <time_frame>Procedural</time_frame>
  </primary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Congestive Heart Failure</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EnSite NavX System</intervention_name>
    <description>EnSite NavX system is a 3D Mapping system</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet criteria for CRT implant including EF&lt;35%, QRS&gt;120ms, NYHA class III or IV&#xD;
&#xD;
          -  Persistent CHF symptoms despite optimization&#xD;
&#xD;
          -  Stable/optimal medical therapy&#xD;
&#xD;
          -  History of ischemic or non-ischemic cardiomyopathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any standard device exclusion including TVR&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Currently participating in IDE/IND study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Berman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

